Lack of Prognostic Relevance of Her-2/neu, Topoisomerase IIα and EGFR in Advanced Ovarian Carcinoma

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Sep 13

PMID 22969977

Citations 4

Authors

Verena Engelstaedter

Judith Boda

Christine Volklein

Jutta Engel

Udo Jeschke

Thomas Kirchner

Doris Mayr

Affiliations

Soon will be listed here.

Abstract

Patients with advanced ovarian cancer (FIGO stage III) have a poor clinical prognosis. However, these patients show distinct differences in their survival time, possibly due to differing responses to chemotherapy and differing tumor biology. In contrast to histological subtype, grading and staging, which are known to affect a patient's prognosis, the impact of the human epidermal growth factor receptor 2 (Her-2/neu), topoisomerase IIα and epidermal growth factor receptor (EGFR) on survival remain inconclusive. Therefore, the aim of this study was to assess their impact on survival in a group of advanced ovarian cancer patients. Tissue microarrays were constructed from specimens of 243 patients. Gene copy and chromosome numbers were evaluated by fluorescence in situ hybridization (FISH) and protein expression by immunohistochemistry (IHC). Scoring for the latter was calculated by considering the percentage of positive tumor cells and the relative staining intensity. FISH results were evaluated by previously published recommendations and correlated with overall survival. Using IHC, 1.6% of the cases that were tested for Her-2/neu and topoisomerase IIα were strongly positive, and 12.3% were positive for EGFR. Using FISH, 4.4% amplifications and 2.1% polysomies for Her-2/neu were identified; topoisomerase IIα showed 2.2% amplifications, 0.4% deletions and 3.5% polysomies. We observed 10.8% high polysomies, but no amplification for EGFR. None of the results obtained by IHC or FISH correlated with overall survival. In general, Her-2/neu, topoisomerase IIα and EGFR may be prognostic factors in ovarian carcinomas. However, within this group of FIGO stage III patients, differences in gene aberration or protein expression were not able to predict differences in survival.

Citing Articles

EGFR-targeted nonviral NIS gene transfer for bioimaging and therapy of disseminated colon cancer metastases.

Urnauer S, Muller A, Schug C, Schmohl K, Tutter M, Schwenk N Oncotarget. 2017; 8(54):92195-92208.

PMID: 29190908 PMC: 5696174. DOI: 10.18632/oncotarget.21028.

Use of Multicenter Data in a Large Cancer Registry for Evaluation of Outcome and Implementation of Novel Concepts.

Schubert-Fritschle G, Combs S, Kirchner T, Nussler V, Engel J Front Oncol. 2017; 7:234.

PMID: 29046867 PMC: 5632760. DOI: 10.3389/fonc.2017.00234.

EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.

Mehner C, Oberg A, Goergen K, Kalli K, Maurer M, Nassar A Genes Cancer. 2017; 8(5-6):589-599.

PMID: 28740577 PMC: 5511892. DOI: 10.18632/genesandcancer.142.

Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR).

Heublein S, Vrekoussis T, Mayr D, Friese K, Lenhard M, Jeschke U J Ovarian Res. 2013; 6(1):6.

PMID: 23339713 PMC: 3557169. DOI: 10.1186/1757-2215-6-6.

References

Pauletti G, Godolphin W, Press M, Slamon D . Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996; 13(1):63-72. View

Kaern J, Aghmesheh M, Nesland J, Danielsen H, Sandstad B, Friedlander M . Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?. Int J Gynecol Cancer. 2005; 15(6):1014-22. DOI: 10.1111/j.1525-1438.2005.00185.x. View

Lee E, Lee Y, Suh D, Kang J, Kim I . Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors. Appl Immunohistochem Mol Morphol. 2009; 18(1):69-74. DOI: 10.1097/PAI.0b013e3181af7d3f. View

Wang J . Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002; 3(6):430-40. DOI: 10.1038/nrm831. View

Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen N . Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl). 2006; 84(8):671-81. DOI: 10.1007/s00109-006-0054-4. View

Goff B, Muntz H, Greer B, Tamimi H, Gown A . Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 1998; 92(1):88-93. DOI: 10.1016/s0029-7844(98)00121-5. View

Stadlmann S, Gueth U, Reiser U, Diener P, Zeimet A, Wight E . Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol. 2006; 19(4):607-10. DOI: 10.1038/modpathol.3800575. View

de Graeff P, Crijns A, de Jong S, Boezen M, Post W, de Vries E . Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer. 2009; 101(1):149-59. PMC: 2713689. DOI: 10.1038/sj.bjc.6605112. View

Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J . Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol. 2010; 136(7):1029-37. DOI: 10.1007/s00432-009-0748-4. View

10.

de Graeff P, Crijns A, ten Hoor K, Klip H, Hollema H, Oien K . The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 2008; 99(2):341-9. PMC: 2480978. DOI: 10.1038/sj.bjc.6604471. View

11.

Dimova I, Raicheva S, Dimitrov R, Doganov N, Toncheva D . Coexistence of copy number increases of c-Myc, ZNF217, CCND1, ErbB1 and ErbB2 in ovarian cancers. Onkologie. 2009; 32(7):405-10. DOI: 10.1159/000219368. View

12.

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View

13.

Farley J, Fuchiuji S, Darcy K, Tian C, Hoskins W, McGuire W . Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol. 2009; 113(3):341-7. PMC: 6944288. DOI: 10.1016/j.ygyno.2009.02.009. View

14.

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Konsgen D . Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol. 2009; 22(4):579-88. DOI: 10.1038/modpathol.2009.14. View

15.

Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujiwara S . Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther. 2010; 11(1):50-7. PMC: 3047101. DOI: 10.4161/cbt.11.1.13877. View

16.

Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, Ballestin C, Colomer R, Cortes-Funes H . Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol. 2008; 10(6):367-71. DOI: 10.1007/s12094-008-0213-x. View

17.

Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S . Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther. 2004; 3(10):1207-14. View

18.

Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M . ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006; 24(26):4317-23. DOI: 10.1200/JCO.2005.04.8397. View

19.

Olsen C, Cnossen J, Green A, Webb P . Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol. 2007; 28(5):376-80. View

20.

Chekerov R, Klaman I, Zafrakas M, Konsgen D, Mustea A, Petschke B . Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia. 2006; 8(1):38-45. PMC: 1584288. DOI: 10.1593/neo.05580. View